0001104659-24-026154.txt : 20240221 0001104659-24-026154.hdr.sgml : 20240221 20240221190042 ACCESSION NUMBER: 0001104659-24-026154 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240216 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Jennifer Kayden CENTRAL INDEX KEY: 0001801372 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 24661698 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 FORMER NAME: FORMER CONFORMED NAME: Chien Jennifer DATE OF NAME CHANGE: 20200128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 tm246920-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-02-16 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001801372 Lee Jennifer Kayden C/O RHYTHM PHARMACEUTICALS, INC. 222 BERKELEY STREET, 12TH FLOOR BOSTON MA 02116 0 1 0 0 EVP, Head of North America 0 Common Stock 2024-02-16 4 A 0 33750 0 A 40602 D Restricted Stock Units 2024-02-16 4 A 0 22000 0 A Common Stock 22000 22000 D Stock Option (Right to Buy) 49.23 2024-02-16 4 A 0 67000 0 A 2034-02-15 Common Stock 67000 67000 D The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. /s/ Hunter Smith, Attorney-in-Fact for Jennifer Kayden Lee 2024-02-21